Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VTVT

vTv Therapeutics Inc

Dec 13 • 04:00PM ET

15.03

Dollar change -0.67
Percentage change -4.27	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX AMGN GILD BIIB INCY NBIX IONS RGEN PTCT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.53	Insider Own	43.20%	Shs Outstand	2.61M	Perf Week	-16.13%
Market Cap	45.89M	Forward P/E	-	EPS next Y	-4.85	Insider Trans	0.38%	Shs Float	1.48M	Perf Month	0.87%
Income	-18.31M	PEG	-	EPS next Q	-0.87	Inst Own	12.84%	Short Float	1.52%	Perf Quarter	5.40%
Sales	1.00M	P/S	45.89	EPS this Y	62.41%	Inst Trans	93.46%	Short Ratio	0.68	Perf Half Y	-29.37%
Book/sh	5.75	P/B	2.62	EPS next Y	-32.88%	ROA	-63.03%	Short Interest	0.02M	Perf Year	46.21%
Cash/sh	13.61	P/C	1.10	EPS next 5Y	-	ROE	-2570.57%	52W Range	7.38 - 30.99	Perf YTD	30.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.96%	ROI	-121.72%	52W High	-51.50%	Beta	0.66
Dividend TTM	-	Quick Ratio	6.69	Sales past 5Y	-26.58%	Gross Margin	91.00%	52W Low	103.66%	ATR (14)	1.18
Dividend Ex-Date	-	Current Ratio	6.69	EPS Y/Y TTM	57.13%	Oper. Margin	-2399.50%	RSI (14)	46.14	Volatility	6.02% 7.80%
Employees	16	Debt/Eq	0.01	Sales Y/Y TTM	11011.11%	Profit Margin	-1830.60%	Recom	1.00	Target Price	35.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	73.16%	Payout	-	Rel Volume	0.23	Prev Close	15.70
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	32.88K	Price	15.03
SMA20	-6.34%	SMA50	0.65%	SMA200	-19.33%	Trades		Volume	7,705	Change	-4.27%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-19	Initiated	H.C. Wainwright	Buy
Apr-10-18	Downgrade	Stifel	Buy → Hold	$12 → $1
Mar-08-18	Initiated	ROTH Capital	Buy	$17
Feb-08-18	Initiated	Northland Capital	Outperform	$28
Sep-26-16	Initiated	H.C. Wainwright	Buy	$13
Sep-04-15	Initiated	Canaccord Genuity	Buy	$15
Aug-24-15	Initiated	Stifel	Buy	$17
Aug-24-15	Initiated	Piper Jaffray	Overweight	$24

Dec-09-24 07:33AM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER (PR Newswire)
Dec-02-24 04:05PM	vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 05:04PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +7.58% +7.12%
04:05PM	vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-26-24 05:01PM	vTv Therapeutics Faces License Agreement Termination (TipRanks)
05:26PM	Loading…
Aug-08-24 05:26PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-24 11:23AM	FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks (Benzinga) -24.53%
06:53AM	FDA places vTv Therapeuticss cadisegliatin programme on clinical hold (Clinical Trials Arena)
Jul-26-24 04:05PM	vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold (GlobeNewswire)
Jun-24-24 04:05PM	vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes (GlobeNewswire)
May-28-24 08:00AM	CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING (PR Newswire) -11.04%
May-20-24 12:00PM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER (PR Newswire)
May-09-24 10:57PM	VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024 (InvestorPlace) +5.22%
05:02PM	VTv Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:51PM	Loading…
04:51PM	vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-24 08:30AM	CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT (PR Newswire)
Mar-13-24 08:24AM	VTv Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-04-24 03:49PM	The Top 3 Healthcare Stocks to Buy on Weakness in 2024 (InvestorPlace) -15.35%
08:00AM	vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes (GlobeNewswire)
Mar-01-24 08:00AM	vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire) -5.70%
Feb-28-24 08:00AM	vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund (GlobeNewswire) +95.88%
Feb-22-24 04:00PM	CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE (PR Newswire)
Nov-09-23 05:06PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.82%
04:30PM	vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-23 08:00AM	vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference (GlobeNewswire)
Nov-02-23 08:00AM	vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-01-23 08:00AM	vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million (GlobeNewswire)
Sep-27-23 08:30AM	CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 (PR Newswire)
08:30AM	Loading…
Sep-26-23 08:30AM	Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer (PR Newswire)
Sep-22-23 05:22AM	3 Tumbling Stocks to Take a Chance On Now (InvestorPlace)
Sep-18-23 08:30AM	CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA (PR Newswire)
Aug-24-23 12:35PM	Is vTv Therapeutics Inc (VTVT) Modestly Undervalued? (GuruFocus.com) -20.58%
Aug-16-23 02:44PM	vTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaq (American City Business Journals)
Aug-11-23 04:37PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-10-23 08:33AM	Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer (PR Newswire) +8.63%
Jun-16-23 08:00AM	vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline (GlobeNewswire) +5.21%
Jun-15-23 07:33AM	CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON (PR Newswire)
May-24-23 09:00AM	vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals (GlobeNewswire)
May-12-23 08:11AM	vTv Therapeutics Insider Ups Holding During Year \ (Simply Wall St.) -5.55%
May-11-23 04:33PM	VTv Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:15PM	vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-20-23 08:00AM	Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 (PR Newswire)
Mar-30-23 08:31AM	Is vTv Therapeutics (NASDAQ:VTVT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-17-23 01:01PM	3 Pharma Stocks That Could Benefit from Global Healthcare Trends (InvestorPlace)
Mar-06-23 06:11PM	VTv Therapeutics: Q4 Earnings Snapshot (AP Finance) +16.32%
05:56PM	vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (GlobeNewswire)
08:02AM	Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases (PR Newswire)
Mar-03-23 05:06AM	vTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 88% if they invested five years ago (Simply Wall St.)
Feb-27-23 08:02AM	Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma (PR Newswire)
Feb-01-23 05:00PM	Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics (GlobeNewswire)
Jan-20-23 09:03AM	Private equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last week (Simply Wall St.)
Jan-09-23 08:00AM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA (PR Newswire)
Dec-22-22 06:00AM	7 Drug Stocks That Will Soar in 2023 (InvestorPlace)
Dec-13-22 08:15AM	vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer (GlobeNewswire) -11.36%
Dec-03-22 07:04AM	Trade Alert: The Independent Director Of vTv Therapeutics Inc. (NASDAQ:VTVT), John Fry, Has Just Spent US$51k Buying A Few More Shares (Simply Wall St.)
Nov-15-22 02:46PM	Three months after leadership change, vTv Therapeutics reports cash of $15.3 million and net loss of $4.3 million in Q3 (American City Business Journals)
Nov-10-22 06:45PM	VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:25PM	vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 07:26AM	Paul Sekhri, new CEO of vTv Therapeutics, touts potential for diabetes drug as he looks to turn biotech around (American City Business Journals)
Sep-23-22 07:04AM	vTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84% (Simply Wall St.) -6.39%
Aug-19-22 12:42PM	This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says (Benzinga)
Aug-18-22 06:41AM	After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 million net loss in Q2 (American City Business Journals) -5.43%
Aug-15-22 06:43PM	vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +6.20% -11.68%
Aug-13-22 08:25AM	What You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor Composition (Simply Wall St.)
Aug-09-22 06:09AM	Months after celebrating its first exit, CinRx invests $10M in newest portfolio company (American City Business Journals)
Jul-27-22 03:01PM	vTv Therapeutics appoints Paul Sehkri as new president and CEO (American City Business Journals)
07:00AM	vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer (GlobeNewswire)
Jul-25-22 08:22AM	vTv Therapeutics Shares Jump On Equity Investment (Benzinga)
07:00AM	vTv Therapeutics Announces Investment by CinRx Pharma (GlobeNewswire)
Jun-04-22 11:00AM	vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes (GlobeNewswire)
Jun-01-22 06:54AM	vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare (GlobeNewswire) +30.62%
May-19-22 06:40AM	3 Oversold Biotech Stocks to Buy Now (InvestorPlace) +12.72%
May-12-22 07:45AM	vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-31-22 07:34PM	vTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 89% if they invested five years ago (Simply Wall St.) -8.60%
Mar-29-22 09:47PM	vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update (PR Newswire)
Mar-03-22 08:48PM	vTv Therapeutics Announces CEO Transition (PR Newswire) -11.54%
Jan-13-22 08:30AM	vTv Therapeutics Shares Updated Corporate Presentation (GlobeNewswire) -6.73%
Jan-12-22 05:38PM	Winthrop Advisory Group LLC Buys Vanguard Extended Market Index ETF, Vanguard Intermediate-Term ... (GuruFocus.com)
Dec-06-21 06:43PM	VTv Therapeutics slashes 65% of workforce, focuses on its diabetes drug (MarketWatch)
05:19PM	vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations (GlobeNewswire)
Dec-03-21 10:00AM	Here's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks (Zacks) -7.32%
Nov-22-21 06:06AM	Triad pharmaceutical company ranks high in Deloittes 2021 Technology Fast 500 list (American City Business Journals)
Nov-09-21 09:45AM	VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:30AM	vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-28-21 03:06PM	Earnings Preview: vTv Therapeutics (VTVT) Q3 Earnings Expected to Decline (Zacks)
01:38PM	Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation (Simply Wall St.)
Oct-20-21 09:00AM	vTv Therapeutics Announces Deepa Prasad as New President and CEO (PR Newswire)
Oct-12-21 07:30AM	vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes (GlobeNewswire) -5.03%
Sep-23-21 04:30PM	vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis (GlobeNewswire)
Sep-13-21 03:40PM	Multiple insiders bought vTv Therapeutics Inc. (NASDAQ:VTVT) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Aug-17-21 10:00AM	Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround (Zacks)
Aug-04-21 07:15PM	VTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:30PM	vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-27-21 07:50AM	vTv Therapeutics (NASDAQ:VTVT) Share Prices Have Dropped 66% In The Last Five Years (Simply Wall St.)
Jun-29-21 07:30AM	vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737 (GlobeNewswire)
Jun-22-21 09:48PM	Where Do Hedge Funds Stand On vTv Therapeutics Inc (VTVT)? (Insider Monkey) +6.78%
10:11AM	vTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer Settings (Benzinga)

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SEKHRI PAUL J	Pres, CEO and Exec Chairperson	Nov 15 '24	Buy	16.65	3,156	52,543	3,156	Nov 19 04:31 PM
SEKHRI PAUL J	Pres, CEO and Exec Chairperson	Nov 18 '24	Buy	16.96	1,844	31,269	5,000	Nov 19 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTVT

vTv Therapeutics Inc

Upgrade your FINVIZ experience